Two experts discuss the importance of diversity when educating and training healthcare workers.
There is a lack of diversity when it comes to physicians in the U.S. In fact, out of the 155 medical schools in the country, the four historically black medical schools have produced more black physicians in the last 10 years than the top 10 medical schools, Valerie Montgomery Rice, M.D., president of Morehouse School of Medicine, said in a recent interview with Managed Healthcare Executive®.
In the interview, Rice and Lloyd Dean, CEO of CommonSpirit Health, a 142-hospital chain headquartered in Chicago, discussed the importance of having African American clinicians in the U.S.
Related: Lloyd Dean and Valerie Montgomery Rice, M.D.: Partnership to Increase Diversity in Healthcare
With COVID-19, African Americans have experienced a disproportional number of deaths and positive cases resulting in hospitalizations.
“And at the core of that problem has been the lack of adequate black and African American physicians and clinicians of color,” Dean said.
As one looks at the physician-patient relationship, if a patient feels comfortable and knows they are dealing with a physician who understands them, the patient is more likely to access the system. Communities of color must align with their physicians, Dean added, to have better outcomes.
In this second part of a two-part podcast episode, Managed Healthcare Executive's Managing Editor Peter Wehrwein spoke with CeCi Connolly and Margaret "Meg" Murray about Medicare Advantage utilization and challenges, highlighting proposed CMS payment cuts and prior authorization issues.
Listen
In this first part of a two-part podcast episode, Managed Healthcare Executive's Managing Editor Peter Wehrwein kicks off our new podcast series "DC Roundtable," with guests Margaret "Meg" Murray, CEO of the Association of Community Affiliated Plans, and member of MHE's Editorial Advisory Board, and CeCi Connolly, president and CEO of the Alliance of Community Health Plans, for a discussion on healthcare policy issues.
Listen
FDA Approves Combination Therapy for Pulmonary Arterial Hypertension
March 26th 2024J&J’s Opsynvi is single-tablet combination of macitentan, an endothelin receptor antagonist, and tadalafil, a PDE5 inhibitor. It will be priced on parity with Opsumit, which is also a J&J product to treat patients with PAH.
Read More